

THE EFFECT OF ERYTHROPOIESIS STIMULATING AGENTS ON MEASURES OF PHYSICAL FUNCTIONING AND EXERCISE TOLERANCE IN CHRONIC RENAL FAILURE PATIENTS ON DIALYSIS: A SYSTEMATIC REVIEW

¹Kirsten Johansen, ²Fred Finkelstein, ³Dennis Revicki, ⁴Matthew Gitlin, ⁵Chris Evans, ⁴Tracy J Mayne. ¹University of California, San Francisco, CA, ²Yale University, New Haven, CT, ³UBC, Bethesda, MD, ⁴Amgen, Thousand Oaks, Ca, ⁵Mapi Values, Boston, MA. The purpose of this study was to review the available evidence on the effect of erythropoiesis stimulating agents (ESA) on physical functioning (PF) and exercise capacity (ET), using VO₂ peak, maximum workload and exercise duration in patients with chronic renal failure who received dialysis. A systematic search was conducted using MEDLINE, and EMBASE. The literature search was limited to papers published in the English language between 1988 and 2008, included all ESA agents, included both randomized clinical trials and observational studies, as long as pre- and post-treatment scores were reported after ESA treatment. Citation-searching of relevant articles also was conducted. 381 potential PF and 213 ET articles were identified. After review of the article abstracts, a total of 80 PF and 46 ET articles were reviewed. Based on this more in-depth evaluation, a total of 12 PF articles [5 studies as with Karnofsky Performance Scale (KPS), 4 studies with Kidney Disease Questionnaire (KDQ), and 3 studies with the Sickness Impact Profile (SIP)] and 29 ET articles [19 studies with VO₂, 16 studies with maximal workload, and 5 studies with exercise duration] were included. PF improved in all 5 studies as measured by the KPS (range: 3.7%-25.8%); in 4 studies as measured by the KDQ Physical Symptoms Score (range: 6.3%-44.4%); and in 3 studies as measured by the SIP Physical Scores (range: 14.3%-61.9%). VO₂ peak increased significantly in all but one of the studies, with a non-significant reduction reported in one study. The average change in VO₂ peak across all studies was 28%. The average change in maximal workload was similar in magnitude to the average change in VO₂peak (26.5%), the average change in exercise duration was 40.7%. In conclusion, the studies and instruments examined above show improvement in scores evaluating PF and ET after the treatment with ESAs.